ScholarIQanswers from OpenAlex & ORCID
Yves Humblet
ResearcherPublications, citations & collaboration network
Yves Humblet is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Yves Humblet have?
ScholarIQindexed works
Yves Humblet has 279 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Yves Humblet have?
ScholarIQcitation count
Yves Humblet has 26,074 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Yves Humblet?
ScholarIQh-index
Yves Humblet has an h-index of 50 in OpenAlex.
What is the i10-index of Yves Humblet?
ScholarIQi10-index
Yves Humblet has an i10-index of 114 in OpenAlex.
What is the OpenAlex record for Yves Humblet?
ScholarIQopenalex
The OpenAlex for Yves Humblet is on the source record.
What are the most-cited papers on Yves Humblet?
ScholarIQmost cited works
KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab
Wendy De Roock, Hubert Piessevaux, Joris De Schutter, M. Janssens, Gert De Hertogh, Nicola Personeni, Bart Biesmans, Jean‐Luc Van Laethem, Marc Peeters, Yves Humblet, Eric Van Cutsem, Sabine Tejpar
Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer
J.-Y. Douillard, Salvatore Siena, J Cassidy, Josep Tabernero, Ronald L. Burkes, Mario Barugel, Yves Humblet, G. Bodoky, David Cunningham, Jacek Jassem, Fernando Rivera, Ilona Kocáková, Paul Ruff, Maria Błasińska-Morawiec, Martin Šmakal, J.-L. Canon, M. Rother, Kelly S. Oliner, Ying Tian, Feng Xu, R. Sidhu
Amphiregulin and Epiregulin mRNA Expression in Primary Tumors Predicts Outcome in Metastatic Colorectal Cancer Treated With Cetuximab
Bart Jacobs, Wendy De Roock, Hubert Piessevaux, Robin Van Oirbeek, Bart Biesmans, Jef De Schutter, Steffen Fieuws, Jo Vandesompele, Marc Peeters, Jean–Luc Van Laethem, Yves Humblet, Frédérique Penault‐Llorca, Gert De Hertogh, Pierre Laurent‐Puig, Eric Van Cutsem, Sabine Tejpar
Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial
Martin Schüler, James Chih‐Hsin Yang, K. Park, Jie‐Hyun Kim, Jaafar Bennouna, Y.-M. Chen, C. Chouaïd, Filippo de Marinis, Jinlun Feng, Francesco Grossi, D.-W. Kim, Xuan Liu, Shun Lü, János Strausz, Yuriy Vinnyk, Rainer Wiewrodt, Caicun Zhou, B. Wang, Vikram K. Chand, David Planchard, Sai‐Hong Ignatius Ou, David Planchard, Keunchil Park, Martin Schüler, James Chih‐Hsin Yang, Vikram K. Chand, Klaus Röhr, Claudia Bagnes, Claudio Martín, Gonzálo Recondo, Juan José Zarbá, C. Blajman, Martin Eduardo Richardet, Sue‐Anne McLachlan, Phillip Parente, Craig Underhill, Catherine Crombie, Paul N. Mainwaring, Richard Greil, Yves Humblet, F. Bustin, L Carestia, Danny Galdermans, Marc Lambrechts, Laetitia Delval, Piet Vercauter, Caicun Zhou, Jin Wang, Cheng Huang, Xiaoyan Lin, Yi‐Long Wu, Xiaoqing Liu, Ying Cheng, Shukui Qin, Jifeng Feng, Jianjin Huang, Yiping Zhang, Shun Lü, Manuela Zereu, Bernardo Garicochea, Cyntia Albuquerque Zadra, Henrik Riska, Tuomo Alanko, Jacques Cadranel, C. Chouaïd, Gérard Zalcman, Denis Moro‐Sibilot, M. Pérol, David Planchard, Jaafar Bennouna, P. Fournel, Radj Gervais, M. Rotarski, Bruno Coudert, Martin Schüler, Michael Thomas, Thomas Wehler, Martin Faehling, Ulrich Keilholz, Eckart Laack, Joachim von Pawel, Rudolf M. Huber, Nicolas Dickgreber, Rainer Wiewrodt, Z. Mark, S. Tehenes, János Strausz, Veronika Sárosi, Kumar Prabhash, Minish Jain, Venkatesan Srinivasan, Lalit Mohan Sharma, H. Dadhich, Rajnish Nagarkar, Amir Onn, Maya Gottfried, Solomon Stemmer, Maria Rita Migliorino, Francesco Grossi, Paolo Bidoli